Jump to content
RemedySpot.com

More on CML

Rate this topic


Guest guest

Recommended Posts

This is an older interview by Schorr, a CLL survivor himself, given by

Dr. Talpaz and Dr. Giles. There is a webcast that you can download rather than

read the interview. I read it and noted that AMN & BMS were in trials, but they

referred to other therapies that targeted mutations were also in the pipes. I

found it interesting and anyway, maybe some of you will, too, especially

newcomers or those worried about what happens if Gleevec doesn't work for them,

there are other drugs forthcoming. I have and perhaps some of you may have

already read some of his other articles.

( Schorr of Seattle is a medical journalist who was diagnosed with chronic

lymphocytic leukemia in 1996. By participating in a clinical trial he has

enjoyed a deep and lasting remission which has enabled him to be a pioneer in

providing authoritative medical information online for other people facing

serious illness. As a passionate patient-advocate, and with support from many of

America's leading medical centers, has hosted and helped produce several

thousand webcasts and videos for patients who have cancer or a wide range of

chronic and acute medical concerns.)

http://www.everydayhealth.com/cancer/webcasts/new-discoveries-in-cml-treatment-t\

ranscript-2.aspx

_____________________________________

PEOPLE WHO STOP DRUGS BECAUSE OF ECONOMIC REASONS

WEDNESDAY, Aug. 4 (HealthDay News) -- In 2009 and 2010, as the economic collapse

shuddered across the globe, oncologists in California noticed a troubling trend:

Three patients who had had serious tumors under control for as long as eight

years reappeared in the clinic with massive cancer regrowth which, in one case,

required emergency surgery.

http://www.everydayhealth.com/publicsite/news/view.aspx?id=641844

____________________________________

Are FDA Regulators Preventing the Terminally Ill From Accessing Promising New

Cancer Drugs?

" Sen. Sam Brownback (R-Kans.) and Rep. Diane (D-Calif.) held a press

conference on May 21 to announce the introduction of the Access, Compassion,

Care, and Ethics for Seriously Ill Patients Act. The ACCESS Act seeks to

increase terminally ill patients' access to promising treatments in the

investigational phase of Food and Drug Administration (FDA) approval. I had the

chance to interview one of the speakers at the press conference, Emil J.

Freireich, M.D., the director of the Adult Leukemia Research Program at M.D.

Cancer Center at The University of Texas. His opinions are quite

provocative. "

http://www.revolutionhealth.com/blogs/valjonesmd/are-fda-regulators-pr-13871

_________________________________

2010 Aug 23;5(8). pii: e12300. Optimizing combination therapies with existing

and future CML drugs.

Abstract

" Small-molecule inhibitors imatinib, dasatinib and nilotinib have been developed

to treat Chromic Myeloid Leukemia (CML). The existence of a

triple-cross-resistant mutation, T315I, has been a challenging problem, which

can be overcome by finding new inhibitors. Many new compounds active against

T315I mutants are now at different stages of development. In this paper we

develop an algorithm which can weigh different combination treatment protocols

according to their cross-resistance properties, and find the protocols with the

highest probability of treatment success. This algorithm also takes into account

drug toxicity by minimizing the number of drugs used, and their concentration.

Although our methodology is based on a stochastic model of CML microevolution,

the algorithm itself does not require measurements of any parameters (such as

mutation rates, or division/death rates of cells), and can be used by medical

professionals without a mathematical background. For illustration, we apply this

algorithm to the mutation data obtained in.........(SORRY, this is short, but it

after all an abstract and more will be released in journals later, but it is

small window of what is developing or already developed.)

http://www.ncbi.nlm.nih.gov/pubmed/20808800

FYI,

Lottie Duthu

Link to comment
Share on other sites

Lottie - Thank you for including this information from Schorr, who I

first in 1987 when he was a medical journalist doing a documentary for a

national cable network. You're right, this is an older interview. He has more

current information at his website http://www.patientpower.info/

and I reconnected after I was diagnosed with CML. I found helpful

information on his PatientPower site, and then I found ! It was a

wonderful reunion. He's in Seattle and I'm in Phoenix, and we got together this

March with several people from the website I work for http://www.empowher.com/,

and is now a contributor. He's a great person to have in your corner, and

is truly dedicated to our best interests. He always welcomes hearing from

patients about what's on our minds, and takes our concerns to the experts when

he interviews them. On a personal level, he has been part of my support team for

the past year, and his prayers and good wishes have helped keep me strong.

Pat in Phoenix

>

> This is an older interview by Schorr, a CLL survivor himself, given by

Dr. Talpaz and Dr. Giles. There is a webcast that you can download rather than

read the interview. I read it and noted that AMN & BMS were in trials, but they

referred to other therapies that targeted mutations were also in the pipes. I

found it interesting and anyway, maybe some of you will, too, especially

newcomers or those worried about what happens if Gleevec doesn't work for them,

there are other drugs forthcoming. I have and perhaps some of you may have

already read some of his other articles.

> ( Schorr of Seattle is a medical journalist who was diagnosed with

chronic lymphocytic leukemia in 1996. By participating in a clinical trial he

has enjoyed a deep and lasting remission which has enabled him to be a pioneer

in providing authoritative medical information online for other people facing

serious illness. As a passionate patient-advocate, and with support from many of

America's leading medical centers, has hosted and helped produce several

thousand webcasts and videos for patients who have cancer or a wide range of

chronic and acute medical concerns.)

>

>

http://www.everydayhealth.com/cancer/webcasts/new-discoveries-in-cml-treatment-t\

ranscript-2.aspx

> _____________________________________

>

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...